Evidence map›Paper›PMID 40661494›Full record

ArticlebioRxiv : the preprint server for biology2025

Beyond the G-Loop: CRBN Molecular Glues Potently Target VAV1 via a Novel SH3 RT-Loop Degron.

Hanfeng Lin, Xin Yu, Haiyang, Ran Cheng, Xiaoli Qi, Yen-Yu Yang, Shengmin Zhou, Xing Che, Jin Wang

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hanfeng LinThe Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.
Xin YuThe Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.
HaiyangThe Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.
Ran ChengThe Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.
Xiaoli QiThe Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.
Yen-Yu YangThermo Fisher Scientific, San Jose, California 95134, United States.
Shengmin ZhouYDS Pharmatech, Inc., Albany, New York 12226, United States.
Xing CheYDS Pharmatech, Inc., Albany, New York 12226, United States.
Jin WangThe Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.ORCID 0000-0003-3625-7919

Funding

Development of First-in-Class RIPK1 Degraders to Improve Cancer ImmunotherapiesR01CA268518 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Jin Wang · 2022 to 2026
$3.5M
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell MalignanciesR01CA250503 · NCI · BAYLOR COLLEGE OF MEDICINE · PI WANG, JIN, WANG, MICHAEL · 2020 to 2024
$3.4M
NCI NIH HHS R01 CA250503NCI NIH HHS R01 CA268518
6 · The paper itself

Abstract

This study reports the discovery and characterization of novel CRBN molecular glues that selectively induce the proteasomal degradation of the hematopoietic-specific signaling protein VAV1, a key target in hematological malignancies and autoimmune diseases. Utilizing unbiased global proteomics, we identified phenyl-glutarimide derivatives NGT-201-12, as effective VAV1 degraders, with its C-terminal SH3 domain (SH3

Identifiers

PMID40661494
PMCPMC12258994

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.